


Accepted Manuscript

Botulinum toxin for chronic migraine: Clinical trials and technical aspects

Cristina Tassorelli, Grazia Sances, Micol Avenali, Roberto De Icco, Daniele Martinelli, Vito Bitetto, Giuseppe Nappi, Giorgio Sandrini



PII: S0041-0101(17)30271-4

DOI: [10.1016/j.toxicon.2017.08.026](https://doi.org/10.1016/j.toxicon.2017.08.026)

Reference: TOXCON 5710

To appear in: *Toxicon*

Received Date: 5 July 2017

Revised Date: 25 August 2017

Accepted Date: 30 August 2017

Please cite this article as: Tassorelli, C., Sances, G., Avenali, M., De Icco, R., Martinelli, D., Bitetto, V., Nappi, G., Sandrini, G., Botulinum toxin for chronic migraine: Clinical trials and technical aspects, *Toxicon* (2017), doi: 10.1016/j.toxicon.2017.08.026.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Botulinum Toxin for Chronic Migraine: Clinical Trials and Technical Aspects

Cristina Tassorelli^{1,2}, Grazia Sances¹, Micol Avenali^{1,2}, Roberto De Icco^{1,2}, Daniele Martinelli^{1,2},
Vito Bitetto¹, Giuseppe Nappi¹, Giorgio Sandrini^{1,2}

¹Headache Science Center and Headache Unit –National Neurological Institute C. Mondino
Foundation, Pavia, Italy

²Dept of Brain and Behavioral Sciences, University of Pavia, Italy

Address for correspondence:

Cristina Tassorelli, M.D., Ph.D.

Via Mondino 2

27100 Pavia, Italy

www.mondino.it

www.unipv.it

Phone: +39 0382380419

e-mail: cristina.tassorelli@unipv.it

Key words: migraine, injection paradigm, exploratory studies, real-life studies, technical issues

Abstract

OnabotulinumtoxinA has been approved for the prophylaxis of chronic migraine following the demonstration of efficacy in two large controlled trials. Data collected from pragmatic studies in the real-life setting have contributed important additional information that are extremely useful for the management of this group of extremely disabled and challenging patients. The main findings from these studies are presented and discussed.

Highlights

- Exploratory trials have documented the efficacy of onabotulinumtoxinA in the prophylaxis of chronic migraine
- Real-life studies are contributing important information to guide the long-term management of patients suffering from chronic migraine in the everyday practice
- Grey areas still exist where recommendations are needed

Download English Version:

<https://daneshyari.com/en/article/8394410>

Download Persian Version:

<https://daneshyari.com/article/8394410>

[Daneshyari.com](https://daneshyari.com)